Investors & Media

Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks

NEURO-TTRansform study met all co-primary and secondary endpoints Positive results to be presented today at AAN 2023 demonstrate eplontersen efficacy, safety and administration profile may provide an important new treatment option in this fatal disease with significant unmet need Ionis to host

Read more
You are now leaving to visit